Overview

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Primary objective of the study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborator:
PeachBowl LegACy Fund
Treatments:
Celecoxib
Cyclophosphamide
Etoposide
Sirolimus